Efficacy of longterm interferon treatment in chronic liver disease evaluated by sensitive polymerase chain reaction assay for hepatitis C virus RNA

Gut

Volumn 37, Issue 5, 1995, Pages 721-726

  Yokosuka, O ^a   Kato, N ^a   Hosoda, K ^a   Ito, Y ^a   Imazeki, F ^a   Ohto, M ^a   Omata, M ^b  

^a CHIBA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Anti HCV antibody; Chronic hepatitis; HCV RNA; Interferon treatment; Polymerase chain reaction

Indexed keywords

ALPHA2A INTERFERON; PLACEBO; VIRUS RNA;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0028827502     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.37.5.721     Document Type: Article

References (31)

1. Dienstag JL. Non-A, non-B hepatitis. I, Recognition, epidemiology, and clinical features. Gastroenterology 1983; 85: 439-62.
2. Alter HJ. Transfusion-associated non-A, non-B, hepatitis: the first decade. In: Zuckerman AJ, ed. Viral hepatitis and liver disease. New York: Alan R Liss, 1988: 537-42.
3. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Bisceglie AD, Peters M, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. N Engl J Med 1986; 315: 1575-8.
4. Omata M, Ito Y, Yokosuka O, Imazeki F, Uchiumi K, Takano S, et al. Histological changes of the liver by treatment of chronic non-A, non-B hepatitis with recombinant leukocyte interferon alpha: comparison with histological changes in chronic hepatitis B. Dig Dis Sci 1989; 34: 330-7.
5. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer Jr HC, Perrilo P, et al. Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized, controlled trial. N Engl J Med 1989; 321: 1501-6.
6. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506-10.
7. Choo Q-L, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood borne non-A, non-B, viral hepatitis genome. Science 1989; 244: 359-62.
8. Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244: 362-4.
9. van der Poel CL, Cuypers HMT, Reesink HW, Weiner AJ, Quan S, di Nello R, et al. Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay. Lancet 1991; 337: 317-9.
10. Kato N, Yokosuka O, Omata M, Hosoda K, Ohto M. Detection of hepatitis C virus ribonucleic acid in the serum by amplification with polymerase chain reaction. J Clin Invest 1990; 86: 1764-7.
11. Hosoda K, Yokosuka O, Omata M, Kato N, Ohto M. Detection and partial sequencing of hepatitis C virus RNA in the liver. Gastroenterology 1991; 101: 766-71.
12. Weiner AJ, Kuo G, Bradley DW, Bonino F, Saracco G, Lee C, et al. Detection of hepatitis C viral sequences in non-A, non-B hepatitis. Lancet 1990; 335: 1-3.
13. Garson JA, Tedder RS, Briggs M, Tuke P, Glazebrook JA, Trute A, et al. Detection of hepatitis C viral sequences in blood donations by 'nested' polymerase chain reaction and prediction of infectivity. Lancet 1990; 335: 1419-22.
14. Okamoto H, Okada S, Sugiyama Y, Tanaka T, Sugai Y, Akahane Y, et al. Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from the 5′ non-coding region. Jpn J Exp Med 1990; 60: 215-22.
15. Castillo I, Bartolome J, Navas S, Gonzalez S, Herrero M, Carreno V. Virological and biochemical long-term follow-up of patients with chronic hepatitis C treated with interferon. Hepatology 1994; 19: 1342-6.
16. Shindo M, Di Bisceglie AM, Cheung L, Shih JM, Baker B, Feinstone SM, et al. Changes in hepatitis C virus RNA in serum associated with alpha interferon therapy. Ann Intern Med 1991; 115: 700-4.
17. Okamoto H, Okada S, Sugiyama Y, Yotsumoto S, Tanaka T, Yoshizawa H, et al. The 5′-terminal sequence of the hepatitis C virus genome. Jpn J Exp Med 1990; 60: 167-77.
18. Kato N, Hijikata M, Ohtsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, et al. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA 1990; 87: 9524-8.
19. Kato N, Yokosuka O, Hosoda K, Ito Y, Ohto M, Omata M. Quantification of hepatitis C virus by competitive reverse transcription-polymerase chain reaction: increase of the virus in advanced liver disease. Hepatology 1993; 18: 16-20.
20. Houghton M, Choo QL, Kuo G. European patent application. Application number 90302866.0 1990.
21. Kubo Y, Takeuchi K, Boonmar S, Katayama T, Choo QL, Kuo G, et al. A cDNA fragment of hepatitis C virus isolated from an implicated donor of post-transfusion non-A, non-B hepatitis in Japan. Nucleic Acids Res 1989; 17: 10367-72.
22. Hoofnagle J, Di Bisceglie AM, Shindo M. Antiviral therapy of hepatiti C - present and future. J Hepatol 1993; 17: S130-6.
23. Reichard O, Forberg U, Fryden A, Mattsson L, Norkrans G, Sonnerborg A, et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-2b for 60 weeks. Hepatology 1994; 19: 280-5.
24. Causse X, Godinot H, Chevallier M, Chosseqros P, Zoulim F, Ouzan D, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A non-B hepatitis. Gastroenterology 1991; 101: 497-502.
25. Saracco G, Rosina F, Torrani Cerenzia MR, Lattore V, Chiandussi L, et al. A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis. J Hepatol 1990; 11: S43-9.
26. Weiland O, Schvarcz R, Wejstal R, Norkrans G, Fryden A. Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alfa-2b: Swedish experience. J Hepatol 1990; 11: S57-62.
27. Camps J, Garcia-Granero M, Riezu-Boj JI, Larrea E, de Alava E, Civeira MP, et al. Prediction of sustained remission of chronic hepatitis C after 12-month course of alfa interferon. J Hepatol 1994; 21: 4-11.
28. Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, et al. Typing hepatitis C virus by polymerase chain reaction with type specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992; 73: 673-9.
29. Bruix J, Barbera JM, Calvet X, Ercilla G, Costa J, Sanchez-Tapias JM, et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989; ii: 1004-6.
30. Colombo M, Kuo G, Choo QL, Donato MF, Del Ninno E, Tommasini MA, et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989; ii: 1006-8.
31. Brillanti S, Masci C, Ricci P, Miglioli M, Barbara L. Significance of IgM antibody to hepatitis C virus in patients with chronic hepatitis C. Hepatology 1992; 15: 998-1001.